Barclays
CDMO

Barclays’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Barclays’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-152,756
Closed -$1.89M – 5665
2024
Q4 		$1.89M Buy
152,756
+18,158
+13% +$208K ﹤0.01% 2933
2024
Q3 		$1.53M Buy
134,598
+66,653
+98% +$669K ﹤0.01% 3064
2024
Q2 		$485K Sell
67,945
-17,737
-21% -$136K ﹤0.01% 3064
2024
Q1 		$574K Sell
85,682
-191,635
-69% -$1.32M ﹤0.01% 3505
2023
Q4 		$1.8M Buy
277,317
+150,706
+119% +$971K ﹤0.01% 2996
2023
Q3 		$1.2M Buy
126,611
+7,072
+6% +$85.1K ﹤0.01% 2205
2023
Q2 		$1.67M Buy
119,539
+33,579
+39% +$572K ﹤0.01% 1996
2023
Q1 		$1.61M Sell
85,960
-102,781
-54% -$1.69M ﹤0.01% 2350
2022
Q4 		$2.6M Buy
188,741
+65,231
+53% +$999K ﹤0.01% 2074
2022
Q3 		$2.36M Buy
123,510
+104,317
+544% +$1.9M ﹤0.01% 1635
2022
Q2 		$293K Sell
19,193
-30,264
-61% -$448K ﹤0.01% 3213
2022
Q1 		$1.01M Sell
49,457
-29,490
-37% -$600K ﹤0.01% 2391
2021
Q4 		$2.3M Buy
78,947
+53,867
+215% +$1.54M ﹤0.01% 2297
2021
Q3 		$542K Buy
25,080
+16,856
+205% +$407K ﹤0.01% 3148
2021
Q2 		$210K Sell
8,224
-47,410
-85% -$1.01M ﹤0.01% 3531
2021
Q1 		$1.01M Buy
55,634
+37,438
+206% +$622K ﹤0.01% 2770
2020
Q4 		$210K Sell
18,196
-7,703
-30% -$70.4K ﹤0.01% 3740
2020
Q3 		$198K Sell
25,899
-5,144
-17% -$39K ﹤0.01% 3855
2020
Q2 		$204K Buy
31,043
+12,206
+65% +$68.1K ﹤0.01% 4060
2020
Q1 		$96K Sell
18,837
-37,227
-66% -$225K ﹤0.01% 4835
2019
Q4 		$430K Buy
56,064
+28,333
+102% +$165K ﹤0.01% 4423
2019
Q3 		$147K Sell
27,731
-8,404
-23% -$52.2K ﹤0.01% 5180
2019
Q2 		$202K Buy
36,135
+21,813
+152% +$89.9K ﹤0.01% 5102
2019
Q1 		$61K Buy
14,322
+14,212
+12,920% +$58K ﹤0.01% 5732
2018
Q4 		$0 Sell
110
-18,887
-99% -$98.5K ﹤0.01% 7424
2018
Q3 		$130K Buy
18,997
+15,277
+411% +$90.6K ﹤0.01% 5340
2018
Q2 		$15K Buy
+3,720
New +$12.9K ﹤0.01% 6350
2016
Q3 		– Sell
-546
Closed -$1K – 6837
2016
Q2 		$1K Buy
+546
New +$1.52K ﹤0.01% 6185
2015
Q4 		– Sell
-149
Closed -$1K – 6684
2015
Q3 		$1K Sell
149
-366
-71% -$3.05K ﹤0.01% 6629
2015
Q2 		$3K Sell
515
-270
-34% -$2.6K ﹤0.01% 6711
2015
Q1 		$5K Sell
785
-1,263
-62% -$12.2K ﹤0.01% 6608
2014
Q4 		$14K Sell
2,048
-941
-31% -$9.48K ﹤0.01% 6537
2014
Q3 		$21K Sell
2,989
-1,726
-37% -$19.3K ﹤0.01% 6459
2014
Q2 		$33K Sell
4,715
-1,538
-25% -$19.4K ﹤0.01% 6224
2014
Q1 		$44K Buy
6,253
+519
+9% +$6.83K ﹤0.01% 6104
2013
Q4 		$40K Sell
5,734
-868
-13% -$8.17K ﹤0.01% 6339
2013
Q3 		$47K Buy
6,602
+5,013
+315% +$49.8K ﹤0.01% 6097
2013
Q2 		$14K Buy
+1,589
New +$16.7K ﹤0.01% 6999

Other funds holding CDMO

TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's CDMO Position: Q1 2025 in Review

Barclays sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 152,756 shares — an estimated $1.89M sold.

Barclays first reported a position in CDMO in Q2 2013 and held it in 38 quarters. The position peaked at $2.6M in Q4 2022. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • Barclays reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Barclays sold 152,756 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $1.89M.
  • Barclays first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2013 and held it in 38 quarters.
  • Barclays's Avid Bioservices, Inc. Common Stock position peaked at $2.6M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.